| Product Code: ETC7277208 | Publication Date: Sep 2024 | Updated Date: Sep 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Georgia Antimicrobial Resistance Market Overview |
3.1 Georgia Country Macro Economic Indicators |
3.2 Georgia Antimicrobial Resistance Market Revenues & Volume, 2021 & 2031F |
3.3 Georgia Antimicrobial Resistance Market - Industry Life Cycle |
3.4 Georgia Antimicrobial Resistance Market - Porter's Five Forces |
3.5 Georgia Antimicrobial Resistance Market Revenues & Volume Share, By Indication, 2021 & 2031F |
3.6 Georgia Antimicrobial Resistance Market Revenues & Volume Share, By Drug Class, 2021 & 2031F |
3.7 Georgia Antimicrobial Resistance Market Revenues & Volume Share, By Mechanism of Action, 2021 & 2031F |
3.8 Georgia Antimicrobial Resistance Market Revenues & Volume Share, By Pathogen, 2021 & 2031F |
4 Georgia Antimicrobial Resistance Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of infectious diseases in Georgia |
4.2.2 Growing awareness about the importance of antimicrobial stewardship |
4.2.3 Rise in healthcare expenditure and investments in healthcare infrastructure in Georgia |
4.3 Market Restraints |
4.3.1 Lack of effective surveillance and monitoring systems for antimicrobial resistance in Georgia |
4.3.2 Limited access to appropriate antibiotics and healthcare services in rural areas |
4.3.3 High cost associated with development and commercialization of new antimicrobial agents |
5 Georgia Antimicrobial Resistance Market Trends |
6 Georgia Antimicrobial Resistance Market, By Types |
6.1 Georgia Antimicrobial Resistance Market, By Indication |
6.1.1 Overview and Analysis |
6.1.2 Georgia Antimicrobial Resistance Market Revenues & Volume, By Indication, 2021- 2031F |
6.1.3 Georgia Antimicrobial Resistance Market Revenues & Volume, By Complicated Urinary Tract Infections (cUTI), 2021- 2031F |
6.1.4 Georgia Antimicrobial Resistance Market Revenues & Volume, By Blood stream infections, 2021- 2031F |
6.1.5 Georgia Antimicrobial Resistance Market Revenues & Volume, By Acute bacterial skin and skin structure infections (ABSSSI), 2021- 2031F |
6.1.6 Georgia Antimicrobial Resistance Market Revenues & Volume, By Hospital acquired bacterial pneumonia and ventilator acquired bacterial pneumonia (HABP and VABP), 2021- 2031F |
6.1.7 Georgia Antimicrobial Resistance Market Revenues & Volume, By Community acquired pneumonia (CAP), 2021- 2031F |
6.1.8 Georgia Antimicrobial Resistance Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Georgia Antimicrobial Resistance Market, By Drug Class |
6.2.1 Overview and Analysis |
6.2.2 Georgia Antimicrobial Resistance Market Revenues & Volume, By Combination therapies, 2021- 2031F |
6.2.3 Georgia Antimicrobial Resistance Market Revenues & Volume, By Tetracyclines, 2021- 2031F |
6.2.4 Georgia Antimicrobial Resistance Market Revenues & Volume, By Cephalosporins, 2021- 2031F |
6.2.5 Georgia Antimicrobial Resistance Market Revenues & Volume, By Glycopeptides and Lipoglycopeptides, 2021- 2031F |
6.2.6 Georgia Antimicrobial Resistance Market Revenues & Volume, By Oxazolidinones, 2021- 2031F |
6.2.7 Georgia Antimicrobial Resistance Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Georgia Antimicrobial Resistance Market, By Mechanism of Action |
6.3.1 Overview and Analysis |
6.3.2 Georgia Antimicrobial Resistance Market Revenues & Volume, By Protein Synthesis Inhibitors, 2021- 2031F |
6.3.3 Georgia Antimicrobial Resistance Market Revenues & Volume, By Cell Wall Synthesis Inhibitors, 2021- 2031F |
6.3.4 Georgia Antimicrobial Resistance Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Georgia Antimicrobial Resistance Market, By Pathogen |
6.4.1 Overview and Analysis |
6.4.2 Georgia Antimicrobial Resistance Market Revenues & Volume, By Klebsiella pneumoniae, 2021- 2031F |
6.4.3 Georgia Antimicrobial Resistance Market Revenues & Volume, By Pseudomonas aeruginosa, 2021- 2031F |
6.4.4 Georgia Antimicrobial Resistance Market Revenues & Volume, By Staphylococcus aureus, 2021- 2031F |
6.4.5 Georgia Antimicrobial Resistance Market Revenues & Volume, By Enterococcus Spp, 2021- 2031F |
6.4.6 Georgia Antimicrobial Resistance Market Revenues & Volume, By Escherichia coli, 2021- 2031F |
6.4.7 Georgia Antimicrobial Resistance Market Revenues & Volume, By Others, 2021- 2031F |
7 Georgia Antimicrobial Resistance Market Import-Export Trade Statistics |
7.1 Georgia Antimicrobial Resistance Market Export to Major Countries |
7.2 Georgia Antimicrobial Resistance Market Imports from Major Countries |
8 Georgia Antimicrobial Resistance Market Key Performance Indicators |
8.1 Percentage of healthcare facilities in Georgia implementing antimicrobial stewardship programs |
8.2 Number of reported cases of multidrug-resistant infections in Georgia |
8.3 Level of government funding allocated to combat antimicrobial resistance in Georgia |
9 Georgia Antimicrobial Resistance Market - Opportunity Assessment |
9.1 Georgia Antimicrobial Resistance Market Opportunity Assessment, By Indication, 2021 & 2031F |
9.2 Georgia Antimicrobial Resistance Market Opportunity Assessment, By Drug Class, 2021 & 2031F |
9.3 Georgia Antimicrobial Resistance Market Opportunity Assessment, By Mechanism of Action, 2021 & 2031F |
9.4 Georgia Antimicrobial Resistance Market Opportunity Assessment, By Pathogen, 2021 & 2031F |
10 Georgia Antimicrobial Resistance Market - Competitive Landscape |
10.1 Georgia Antimicrobial Resistance Market Revenue Share, By Companies, 2024 |
10.2 Georgia Antimicrobial Resistance Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here